Black currant oil
This article was originally published in The Tan Sheet
Executive Summary
In an Aug. 11 letter to Rep. Henry Waxman (D-Calif.), Traco Labs noted the "dramatic difference between what FDA told Congress about" BCO in a May 19 enforcement report on dietary supplements and "what they now state and confirm in response to" a Freedom of Information Act request from Traco. The firm submitted an Fol request to FDA in June asking for documentation to support a statement in the FDA report that gama linolenic acid, a component of BCO, poses serious health concerns ("The Tan Sheet" May 31, p. 3). FDA responded to Traco on Aug. 5 that "we have searched our files and find no responsive information or documents" to support the claim that gama linolenic acid is unsafe.